NYSE:INO
Inovio Pharmaceuticals Stock News
$12.10
+0.0900 (+0.749%)
At Close: May 03, 2024
Inovio Pharmaceuticals, Inc. (INO) Jefferies Healthcare Conference 2023 (Transcript)
10:17am, Friday, 09'th Jun 2023
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Jefferies Healthcare Conference 2023 June 9, 2023 8:00 PM ET Company Participants Jacqueline Shea - President & CEO Michael Sumner - CMO Conference Call Part
INOVIO to Present at the 2023 Jefferies Healthcare Conference
08:00am, Thursday, 25'th May 2023
PLYMOUTH MEETING, Pa. , May 25, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel
INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up
09:28am, Wednesday, 24'th May 2023
INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug designation from the European Commission.
Inovio Pharmaceuticals, Inc. (INO) 2023 RBC Capital Markets Global Healthcare Conference (Transcript)
06:55pm, Wednesday, 17'th May 2023
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 4:05 PM ET Company Participants Greg Renza - Biotechnology Equity Research Analyst, RBC Co
All You Need to Know About Inovio (INO) Rating Upgrade to Buy
01:41pm, Monday, 15'th May 2023
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates
06:59pm, Wednesday, 10'th May 2023
Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.36 per share a year ago.
Penny Stocks To Buy? 10 Under $1 To Watch This Week
03:29pm, Wednesday, 19'th Apr 2023
Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
01:55pm, Monday, 17'th Apr 2023
Merck's decision to pay top dollar for a late-stage asset is sparking a wave of bargain buying in biotech today. Agenus, Inovio Pharmaceuticals, and Roivant Sciences are three of the biggest beneficia
Penny Stocks To Buy? 7 Under $1 To Watch This Week
11:15am, Monday, 17'th Apr 2023
Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy?
Why Inovio Pharmaceuticals' Shares Jumped on Thursday
02:07pm, Thursday, 13'th Apr 2023
Inovio's shares are down more than 43% this year. The company said it has enough cash to last into the first quarter of 2025.
Top Penny Stocks To Buy Now? 10 To Watch Under $5
11:27am, Thursday, 13'th Apr 2023
10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Shares of Inovio Pharmaceuticals Were Down Tuesday
03:10pm, Tuesday, 04'th Apr 2023
Inovio said it has enough cash to fund operations into the first quarter of 2025. The company focuses on DNA medicines to treat HPV diseases, cancer, and infectious diseases.
INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference
08:00am, Friday, 03'rd Mar 2023
PLYMOUTH MEETING, Pa. , March 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel
Inovio Pharmaceuticals, Inc. (INO) Q4 2022 Earnings Call Transcript
07:58pm, Wednesday, 01'st Mar 2023
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Thomas Hong - Manager-Investor Communications Jacqueline Shea - President and
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates
07:34pm, Wednesday, 01'st Mar 2023
Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?